\documentclass[11pt,twoside]{article}\makeatletter

\IfFileExists{xcolor.sty}%
  {\RequirePackage{xcolor}}%
  {\RequirePackage{color}}
\usepackage{colortbl}
\usepackage{wrapfig}
\usepackage{ifxetex}
\ifxetex
  \usepackage{fontspec}
  \usepackage{xunicode}
  \catcode`⃥=\active \def⃥{\textbackslash}
  \catcode`❴=\active \def❴{\{}
  \catcode`❵=\active \def❵{\}}
  \def\textJapanese{\fontspec{Noto Sans CJK JP}}
  \def\textChinese{\fontspec{Noto Sans CJK SC}}
  \def\textKorean{\fontspec{Noto Sans CJK KR}}
  \setmonofont{DejaVu Sans Mono}
  
\else
  \IfFileExists{utf8x.def}%
   {\usepackage[utf8x]{inputenc}
      \PrerenderUnicode{–}
    }%
   {\usepackage[utf8]{inputenc}}
  \usepackage[english]{babel}
  \usepackage[T1]{fontenc}
  \usepackage{float}
  \usepackage[]{ucs}
  \uc@dclc{8421}{default}{\textbackslash }
  \uc@dclc{10100}{default}{\{}
  \uc@dclc{10101}{default}{\}}
  \uc@dclc{8491}{default}{\AA{}}
  \uc@dclc{8239}{default}{\,}
  \uc@dclc{20154}{default}{ }
  \uc@dclc{10148}{default}{>}
  \def\textschwa{\rotatebox{-90}{e}}
  \def\textJapanese{}
  \def\textChinese{}
  \IfFileExists{tipa.sty}{\usepackage{tipa}}{}
\fi
\def\exampleFont{\ttfamily\small}
\DeclareTextSymbol{\textpi}{OML}{25}
\usepackage{relsize}
\RequirePackage{array}
\def\@testpach{\@chclass
 \ifnum \@lastchclass=6 \@ne \@chnum \@ne \else
  \ifnum \@lastchclass=7 5 \else
   \ifnum \@lastchclass=8 \tw@ \else
    \ifnum \@lastchclass=9 \thr@@
   \else \z@
   \ifnum \@lastchclass = 10 \else
   \edef\@nextchar{\expandafter\string\@nextchar}%
   \@chnum
   \if \@nextchar c\z@ \else
    \if \@nextchar l\@ne \else
     \if \@nextchar r\tw@ \else
   \z@ \@chclass
   \if\@nextchar |\@ne \else
    \if \@nextchar !6 \else
     \if \@nextchar @7 \else
      \if \@nextchar (8 \else
       \if \@nextchar )9 \else
  10
  \@chnum
  \if \@nextchar m\thr@@\else
   \if \@nextchar p4 \else
    \if \@nextchar b5 \else
   \z@ \@chclass \z@ \@preamerr \z@ \fi \fi \fi \fi
   \fi \fi  \fi  \fi  \fi  \fi  \fi \fi \fi \fi \fi \fi}
\gdef\arraybackslash{\let\\=\@arraycr}
\def\@textsubscript#1{{\m@th\ensuremath{_{\mbox{\fontsize\sf@size\z@#1}}}}}
\def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}}
\def\abbr{}
\def\corr{}
\def\expan{}
\def\gap{}
\def\orig{}
\def\reg{}
\def\ref{}
\def\sic{}
\def\persName{}\def\name{}
\def\placeName{}
\def\orgName{}
\def\textcal#1{{\fontspec{Lucida Calligraphy}#1}}
\def\textgothic#1{{\fontspec{Lucida Blackletter}#1}}
\def\textlarge#1{{\large #1}}
\def\textoverbar#1{\ensuremath{\overline{#1}}}
\def\textquoted#1{‘#1’}
\def\textsmall#1{{\small #1}}
\def\textsubscript#1{\@textsubscript{\selectfont#1}}
\def\textxi{\ensuremath{\xi}}
\def\titlem{\itshape}
\newenvironment{biblfree}{}{\ifvmode\par\fi }
\newenvironment{bibl}{}{}
\newenvironment{byline}{\vskip6pt\itshape\fontsize{16pt}{18pt}\selectfont}{\par }
\newenvironment{citbibl}{}{\ifvmode\par\fi }
\newenvironment{docAuthor}{\ifvmode\vskip4pt\fontsize{16pt}{18pt}\selectfont\fi\itshape}{\ifvmode\par\fi }
\newenvironment{docDate}{}{\ifvmode\par\fi }
\newenvironment{docImprint}{\vskip 6pt}{\ifvmode\par\fi }
\newenvironment{docTitle}{\vskip6pt\bfseries\fontsize{22pt}{25pt}\selectfont}{\par }
\newenvironment{msHead}{\vskip 6pt}{\par}
\newenvironment{msItem}{\vskip 6pt}{\par}
\newenvironment{rubric}{}{}
\newenvironment{titlePart}{}{\par }

\newcolumntype{L}[1]{){\raggedright\arraybackslash}p{#1}}
\newcolumntype{C}[1]{){\centering\arraybackslash}p{#1}}
\newcolumntype{R}[1]{){\raggedleft\arraybackslash}p{#1}}
\newcolumntype{P}[1]{){\arraybackslash}p{#1}}
\newcolumntype{B}[1]{){\arraybackslash}b{#1}}
\newcolumntype{M}[1]{){\arraybackslash}m{#1}}
\definecolor{label}{gray}{0.75}
\def\unusedattribute#1{\sout{\textcolor{label}{#1}}}
\DeclareRobustCommand*{\xref}{\hyper@normalise\xref@}
\def\xref@#1#2{\hyper@linkurl{#2}{#1}}
\begingroup
\catcode`\_=\active
\gdef_#1{\ensuremath{\sb{\mathrm{#1}}}}
\endgroup
\mathcode`\_=\string"8000
\catcode`\_=12\relax

\usepackage[a4paper,twoside,lmargin=1in,rmargin=1in,tmargin=1in,bmargin=1in,marginparwidth=0.75in]{geometry}
\usepackage{framed}

\definecolor{shadecolor}{gray}{0.95}
\usepackage{longtable}
\usepackage[normalem]{ulem}
\usepackage{fancyvrb}
\usepackage{fancyhdr}
\usepackage{graphicx}
\usepackage{marginnote}

\renewcommand{\@cite}[1]{#1}


\renewcommand*{\marginfont}{\itshape\footnotesize}

\def\Gin@extensions{.pdf,.png,.jpg,.mps,.tif}

  \pagestyle{fancy}

\usepackage[pdftitle={Scan to know paper details and author's profile},
 pdfauthor={}]{hyperref}
\hyperbaseurl{}

	 \paperwidth210mm
	 \paperheight297mm
              
\def\@pnumwidth{1.55em}
\def\@tocrmarg {2.55em}
\def\@dotsep{4.5}
\setcounter{tocdepth}{3}
\clubpenalty=8000
\emergencystretch 3em
\hbadness=4000
\hyphenpenalty=400
\pretolerance=750
\tolerance=2000
\vbadness=4000
\widowpenalty=10000

\renewcommand\section{\@startsection {section}{1}{\z@}%
     {-1.75ex \@plus -0.5ex \@minus -.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\Large\bfseries}}
\renewcommand\subsection{\@startsection{subsection}{2}{\z@}%
     {-1.75ex\@plus -0.5ex \@minus- .2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\Large}}
\renewcommand\subsubsection{\@startsection{subsubsection}{3}{\z@}%
     {-1.5ex\@plus -0.35ex \@minus -.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\large}}
\renewcommand\paragraph{\@startsection{paragraph}{4}{\z@}%
     {-1ex \@plus-0.35ex \@minus -0.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\normalsize}}
\renewcommand\subparagraph{\@startsection{subparagraph}{5}{\parindent}%
     {1.5ex \@plus1ex \@minus .2ex}%
     {-1em}%
     {\reset@font\normalsize\bfseries}}


\def\l@section#1#2{\addpenalty{\@secpenalty} \addvspace{1.0em plus 1pt}
 \@tempdima 1.5em \begingroup
 \parindent \z@ \rightskip \@pnumwidth 
 \parfillskip -\@pnumwidth 
 \bfseries \leavevmode #1\hfil \hbox to\@pnumwidth{\hss #2}\par
 \endgroup}
\def\l@subsection{\@dottedtocline{2}{1.5em}{2.3em}}
\def\l@subsubsection{\@dottedtocline{3}{3.8em}{3.2em}}
\def\l@paragraph{\@dottedtocline{4}{7.0em}{4.1em}}
\def\l@subparagraph{\@dottedtocline{5}{10em}{5em}}
\@ifundefined{c@section}{\newcounter{section}}{}
\@ifundefined{c@chapter}{\newcounter{chapter}}{}
\newif\if@mainmatter 
\@mainmattertrue
\def\chaptername{Chapter}
\def\frontmatter{%
  \pagenumbering{roman}
  \def\thechapter{\@roman\c@chapter}
  \def\theHchapter{\roman{chapter}}
  \def\thesection{\@roman\c@section}
  \def\theHsection{\roman{section}}
  \def\@chapapp{}%
}
\def\mainmatter{%
  \cleardoublepage
  \def\thechapter{\@arabic\c@chapter}
  \setcounter{chapter}{0}
  \setcounter{section}{0}
  \pagenumbering{arabic}
  \setcounter{secnumdepth}{6}
  \def\@chapapp{\chaptername}%
  \def\theHchapter{\arabic{chapter}}
  \def\thesection{\@arabic\c@section}
  \def\theHsection{\arabic{section}}
}
\def\backmatter{%
  \cleardoublepage
  \setcounter{chapter}{0}
  \setcounter{section}{0}
  \setcounter{secnumdepth}{2}
  \def\@chapapp{\appendixname}%
  \def\thechapter{\@Alph\c@chapter}
  \def\theHchapter{\Alph{chapter}}
  \appendix
}
\newenvironment{bibitemlist}[1]{%
   \list{\@biblabel{\@arabic\c@enumiv}}%
       {\settowidth\labelwidth{\@biblabel{#1}}%
        \leftmargin\labelwidth
        \advance\leftmargin\labelsep
        \@openbib@code
        \usecounter{enumiv}%
        \let\p@enumiv\@empty
        \renewcommand\theenumiv{\@arabic\c@enumiv}%
	}%
  \sloppy
  \clubpenalty4000
  \@clubpenalty \clubpenalty
  \widowpenalty4000%
  \sfcode`\.\@m}%
  {\def\@noitemerr
    {\@latex@warning{Empty `bibitemlist' environment}}%
    \endlist}

\def\tableofcontents{\section*{\contentsname}\@starttoc{toc}}
\parskip0pt
\parindent1em
\def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}}
\newenvironment{reflist}{%
  \begin{raggedright}\begin{list}{}
  {%
   \setlength{\topsep}{0pt}%
   \setlength{\rightmargin}{0.25in}%
   \setlength{\itemsep}{0pt}%
   \setlength{\itemindent}{0pt}%
   \setlength{\parskip}{0pt}%
   \setlength{\parsep}{2pt}%
   \def\makelabel##1{\itshape ##1}}%
  }
  {\end{list}\end{raggedright}}
\newenvironment{sansreflist}{%
  \begin{raggedright}\begin{list}{}
  {%
   \setlength{\topsep}{0pt}%
   \setlength{\rightmargin}{0.25in}%
   \setlength{\itemindent}{0pt}%
   \setlength{\parskip}{0pt}%
   \setlength{\itemsep}{0pt}%
   \setlength{\parsep}{2pt}%
   \def\makelabel##1{\upshape ##1}}%
  }
  {\end{list}\end{raggedright}}
\newenvironment{specHead}[2]%
 {\vspace{20pt}\hrule\vspace{10pt}%
  \phantomsection\label{#1}\markright{#2}%

  \pdfbookmark[2]{#2}{#1}%
  \hspace{-0.75in}{\bfseries\fontsize{16pt}{18pt}\selectfont#2}%
  }{}
      \def\TheFullDate{1970-01-01 (revised: 01 January 1970)}
\def\TheID{\makeatother }
\def\TheDate{1970-01-01}
\title{Scan to know paper details and author's profile}
\author{}\makeatletter 
\makeatletter
\newcommand*{\cleartoleftpage}{%
  \clearpage
    \if@twoside
    \ifodd\c@page
      \hbox{}\newpage
      \if@twocolumn
        \hbox{}\newpage
      \fi
    \fi
  \fi
}
\makeatother
\makeatletter
\thispagestyle{empty}
\markright{\@title}\markboth{\@title}{\@author}
\renewcommand\small{\@setfontsize\small{9pt}{11pt}\abovedisplayskip 8.5\p@ plus3\p@ minus4\p@
\belowdisplayskip \abovedisplayskip
\abovedisplayshortskip \z@ plus2\p@
\belowdisplayshortskip 4\p@ plus2\p@ minus2\p@
\def\@listi{\leftmargin\leftmargini
               \topsep 2\p@ plus1\p@ minus1\p@
               \parsep 2\p@ plus\p@ minus\p@
               \itemsep 1pt}
}
\makeatother
\fvset{frame=single,numberblanklines=false,xleftmargin=5mm,xrightmargin=5mm}
\fancyhf{} 
\setlength{\headheight}{14pt}
\fancyhead[LE]{\bfseries\leftmark} 
\fancyhead[RO]{\bfseries\rightmark} 
\fancyfoot[RO]{}
\fancyfoot[CO]{\thepage}
\fancyfoot[LO]{\TheID}
\fancyfoot[LE]{}
\fancyfoot[CE]{\thepage}
\fancyfoot[RE]{\TheID}
\hypersetup{citebordercolor=0.75 0.75 0.75,linkbordercolor=0.75 0.75 0.75,urlbordercolor=0.75 0.75 0.75,bookmarksnumbered=true}
\fancypagestyle{plain}{\fancyhead{}\renewcommand{\headrulewidth}{0pt}}

\date{}
\usepackage{authblk}

\providecommand{\keywords}[1]
{
\footnotesize
  \textbf{\textit{Index terms---}} #1
}

\usepackage{graphicx,xcolor}
\definecolor{GJBlue}{HTML}{273B81}
\definecolor{GJLightBlue}{HTML}{0A9DD9}
\definecolor{GJMediumGrey}{HTML}{6D6E70}
\definecolor{GJLightGrey}{HTML}{929497} 

\renewenvironment{abstract}{%
   \setlength{\parindent}{0pt}\raggedright
   \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}}
   \vskip16pt
   \textcolor{GJBlue}{\large\bfseries\abstractname\space}
}{%   
   \vskip8pt
   \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}}
   \vskip16pt
}

\usepackage[absolute,overlay]{textpos}

\makeatother 
      \usepackage{lineno}
      \linenumbers
      
\begin{document}

             \affil[1]{  }

\renewcommand\Authands{ and }

\date{\small \em Received: 1 January 1970 Accepted: 1 January 1970 Published: 1 January 1970}

\maketitle


\begin{abstract}
        


Background: Lujo virus (LUJV) is a highly fatal human pathogen belonging to the Arenaviridae family. Lujo virus causes viral hemorrhagic fever (VHF). An In silico molecular docking was performed on the GPC domain of Lujo virus in complex with the first CUB domain of neuropilin-2.The aim of this study is to predict an effective epitope-based vaccine against the glycoprotein GPC precursor of Lujo virus using immunoinformatics approaches. Methods and Materials: A glycoprotein GPC precursor of Lujo virus Sequence was retrieved from NCBI. Different prediction tools were then used to analyze the nominee's epitopes in BepiPred-2.0: Sequential B-Cell Epitope Predictor for B-cell, T-cell MHC class II & I. Later the proposed peptides were docked using the Autodock 4.0 software program.

\end{abstract}


\keywords{}

\begin{textblock*}{18cm}(1cm,1cm) % {block width} (coords) 
\textcolor{GJBlue}{\LARGE Global Journals \LaTeX\ JournalKaleidoscope\texttrademark}
\end{textblock*}

\begin{textblock*}{18cm}(1.4cm,1.5cm) % {block width} (coords) 
\textcolor{GJBlue}{\footnotesize \\ Artificial Intelligence formulated this projection for compatibility purposes from the original article published at Global Journals. However, this technology is currently in beta. \emph{Therefore, kindly ignore odd layouts, missed formulae, text, tables, or figures.}}
\end{textblock*}


\begin{textblock*}{10cm}(1.05cm,3cm)
{{\textit{CrossRef DOI of original article:}} \underline{}}
\end{textblock*}\let\tabcellsep& 	 	 		 
\section[{INTRODUCTION}]{INTRODUCTION}\par
Arenaviruses are rodent-borne viruses. Where a genetically unique arenavirus called Lujo virus, has been discovered as the causal agent of a nosocomial outbreak of acute febrile disease with hemorrhagic manifestations in Zambia and South Africa. The outbreak marked a high case fatality rate of almost 80\% \hyperref[b0]{[1]} . These viruses are genetically and geographically related to the Old World mammarena viruses, endemic to West Africa, and the New World mammarena viruses, endemic to South and North America \hyperref[b1]{[2]} . Lujo virus causes viral hemorrhagic fever (VHF) which can be caused by five distinct families of viruses: the filo-, arena-, flavi-, rhabdo-and bunya virus family \hyperref[b2]{[3]} . Viral hemorrhagic fever (VHF) is an acute systemic illness classically involving fever, a constellation of initially nonspecific signs and symptoms, and a propensity for bleeding and shock.\par
With Lujo virus hemorrhagic fever (LVHF) illness typically begins with the abrupt onset of fever, malaise, headache, and myalgias followed successively by a sore throat, chest pain, gastrointestinal symptoms, rash, minor hemorrhage, subconjunctival injection, and neck and facial swelling over the first week of sickness [4]   . No major hemorrhage was noted. Whereas neurological signs were sometimes seen in the late stages, shock and multi-organ system failure, often with evidence of disseminated intravascular coagulopathy, ensued in the second week, with death in four of the five cases \hyperref[b3]{[4]} .\par
There are currently limited preventative and therapeutic options for patients infected with these highly pathogenic viruses \hyperref[b4]{[5]} .\par
Arenaviruses are enveloped negative-strand RNA viruses with a genome that is bi-segmented into S and L segments. The S segment encodes a nucleocapsid protein (NP) and an envelope glycoprotein precursor (GPC); the L segment encodes a matrix protein (Z) and an RNA-dependent RNA polymerase (L). The GPC is synthesized as a single polypeptide and undergoes processing by the host cell signal peptidase (SP ase) and subtilisin-like kexinisozyme-1/site-1protease (SKI-1/S1P), yielding typical receptor binding (G1), transmembrane fusion (G2), and stable signal peptide (SSP) subunits, respectively [6-8]   . Viral entry into target cells is initiated by the binding of G1 to appropriate cell surface receptors. The first cellular receptor for arenavirus to be identified was\textunderscore -dystroglycan (\textunderscore DG), a ubiquitous receptor for extracellular matrix proteins \hyperref[b8]{[9]} . The understanding of epitope/antibody interaction is the key to constructing potent vaccines and effective diagnostics. The host defense mechanisms against viruses generally vary from germline-encoded immunity, which present early in the evolution of microorganisms to activation and induction of specific adaptive immune responses by the production of Th-1 andTh-2 cytokines. B-cells recognize antigens via membrane bound antibodies using B-cell receptors (BCRs), resulting in the secretion of antibodies that bind to the antigen and deactivate or remove it. Processing and presentation of peptide epitopes are essential steps in cellmediated immunity \hyperref[b9]{[10]} . Lujo virus (LUJV) is a highly fatal human pathogen belonging to the Arenaviridae family. This virus is unique; as it uses neuropilin-2 (NRP2) as a cellular receptor.\par
Previous study revealed that the GP1 receptor-binding domain of LUJV (LUJVGP1) recognizes NRP2, where its recognition is metal-ion dependent. The binding of a Ca2 + ion stabilizes the conformations of Asp127 and Glu79 from NRP2 pre-organizing them for interaction with Lys110 of LUJVGP1. CUB domain of NRP2 is almost completely conserved among humans, mice, rats and bats, and the only slight variations occur outside of the binding site for LUJV. Hence all of these animal species have a potential to serve as reservoirs for LUJV, considering only the compatibility to NRP2 \hyperref[b1]{[2]} . In silico molecular docking was performed on the GP1 domain of Lujo virus in complex with the first CUB domain of neuropilin-2 \hyperref[b1]{[2]} . The aim of the study is to predict an effective epitope-based vaccine against an envelope glycoprotein precursor (GPC); of Lujo virus. The development of immunogenetics approaches will enhance the understanding of the genetic factors impact on the interindividual and interpopulation variations in immune responses to vaccines that could be helpful to progress new vaccine strategies \hyperref[b10]{[11]} . In silico/reverse vaccinology had replaced conventional culture-based vaccine because it reduces the cost required for laboratory investigation of pathogen, also speeding up the time needed to achieve the results \hyperref[b11]{[12,}\hyperref[b12]{13]} .\par
Therefore, using immunoinformatics approaches to predict this new kind of vaccines could be a London Journal of Research in Computer Science and Technology magnificently additive in the way forward of preventing Lujo virus. Normally, the investigation of the binding affinity of antigenic peptides to the MHC molecules is the main goal when predicting epitopes. The usage of such tools and information leads to the development of new vaccines. While these approaches permit the optimization of a London Journal of Research in Computer Science and Technology vaccine for a specific population, It's probably can be reformulated to design a "universal vaccine" a vaccine that provides maximum coverage for the whole worlds' population \hyperref[b13]{[14]}\hyperref[b14]{[15]}\hyperref[b15]{[16]}\hyperref[b16]{[17]} . In this study, we focused on both MHC class II and class I with performing of molecular docked in HLA-A0201.  
\section[{II. MATERIALS AND METHODS}]{II. MATERIALS AND METHODS} 
\section[{Sequences Retrieval}]{Sequences Retrieval}\par
The amino acids sequences of Glycoprotein GPC (Glycoside hydrolase family) of Lujo virus were retrieved from the NCBI database (https:// www.ncbi.nlm.nih.gov/protein) \hyperref[b17]{[18]} in FASTA format on July 2018. Different prediction tools of Immune Epitope Database IEDB analysis resource (http://www.iedb.org/) \hyperref[b18]{[19]} were then used to analyze the candidate epitopes as shown on figure (1). 
\section[{Conservation Region and Physicochemical Properties}]{Conservation Region and Physicochemical Properties}\par
Conservation regions were determined using multiple sequence alignment with the help of Clustal-W in the BioEdit software version 7.2.5 [20]   . Epitope conservancy prediction for individual epitopes was then calculated using the IEDB analysis resource. Conservancy can be defined as the portion of protein sequences that restrain the epitope measured at or exceeding a specific level of identity \hyperref[b20]{[21]} . The physicochemical properties of the retrieved sequence; molecular weight and amino acid composition; were also determined by BioEdit software version 7.2.5 \hyperref[b19]{[20]} . 
\section[{B Cell Epitope Prediction Tools}]{B Cell Epitope Prediction Tools}\par
Candidate epitopes were analyzed using several B-cell prediction methods to determine their antigenicity, flexibility, hydrophilicity, and surface accessibility. The linear prediction epitopes were obtained from the Immune epitope database (http://tools.iedb.org/bcell/result/) \hyperref[b21]{[22]} by using the BepiPred test with a threshold value of 0.149 and a window size of 6.0. Moreover, surface-accessible epitopes were predicated with a threshold value of 1.0 and window size of 6.0 using the Emini surface accessibility prediction tool \hyperref[b22]{[23]} .\par
Kolaskar and Tongaonker antigenicity methods (http://tools.iedb.org/bcell/result/) were proposed to determine the sites of antigenic epitopes with a default threshold value of 1.030 and a window size of 6.0 \hyperref[b23]{[24]} . 
\section[{T cell epitope prediction tools 2.4.1 Peptide binding to MHC class I molecules}]{T cell epitope prediction tools 2.4.1 Peptide binding to MHC class I molecules}\par
The peptide binding was assessed by IEDB MHC class I prediction tool at http://tools.iedb. org/mhc1. This tool employs different methods to determine the ability of submitted sequence to bind to a specific MHC class I molecule. The artificial neural network (ANN) method \hyperref[b24]{[25,}\hyperref[b25]{26]} was used to calculate IC50 values of peptide binding to MHC-class I molecules. For both frequent and non-frequent alleles, peptide length was set to 9 amino acids earlier to the prediction. The alleles having binding affinity IC50 equal to or less than 500 nM were considered for further analysis. The affinity of 500 nM is routinely used as a threshold for peptide selection and it captures 92\% of the epitopes \hyperref[b26]{[27]}\hyperref[b27]{[28]}\hyperref[b28]{[29]} . 
\section[{Peptide Binding to MHC Class II Molecules}]{Peptide Binding to MHC Class II Molecules}\par
MHC class II prediction tool http://tools. iedb.org/mhcII provided by Immune Epitope Database (IEDB) analysis resource and human allele references set was used to predict the peptide binding to MHC class II molecules. Where the Artificial Neural Network prediction method was chosen to identify the binding affinity to MHC class II grooves and MHC class II binding core epitopes. All epitopes that bind to as many alleles at score equal to or less than 1000 half-maximal inhibitory concentration (IC50) were selected for further analysis. \hyperref[b29]{[30]} . 
\section[{Population Coverage}]{Population Coverage}\par
Population coverage for each epitope was calculated by the IEDB population coverage tool at http://tools.iedb.org/tools/population/iedb\textunderscore  input \hyperref[b30]{[31]} . This tool was targeted in order to determine the fraction of individual alleles predicted to respond to a given set of epitopes with known MHC restrictions. For every single population coverage, the tool computed the following information: molecules were assessed against a population coverage area selected prior to the submission. 
\section[{Homology Modeling}]{Homology Modeling}\par
The 3D structure of glycoprotein GPC of Lujo virus was predicted using Raptor X web portal (http://raptorx.uchicago.edu/) \hyperref[b31]{[32]} . The reference sequence was submitted in FASTA format on 14/9/2018 and the structure was received on 15/9/2018. Subsequently the structure was treated with UCSF Chimera 1.10.2 \hyperref[b32]{[33]} to visualize the position of the proposed peptides. 
\section[{In Silico Molecular Docking 2.7.1 Ligand Preparation}]{In Silico Molecular Docking 2.7.1 Ligand Preparation}\par
In order to estimate the binding affinities between the epitopes and the molecular structure of MHC class I \& MHC class II, in silico molecular docking was utilized. The proposed epitopes sequences were then selected from the Lujo virus reference sequence using Chimera 1.10 and saved as a "pdb" file. The obtained files were later optimized and energy minimized. The HLA-A0201 was selected as the macromolecule for docking; as HLA-A0201 is considered as the most popular MHC allele and most MHC-I epitopes were nonapeptides \hyperref[b33]{[34]} .\par
Its crystal structure (4UQ3) was downloaded from the RCSB Protein Data Bank (http://www. rcsb.org/pdb/home/home.do), which was in complex with an azobenzene-containing peptide [35]   .\par
The crystal structure of LUJVGP1/NRP2 was retrieved from protein databank (PDB ID: 6GH8) [2]   . 
\section[{Molecular Docking}]{Molecular Docking}\par
Molecular docking was performed using Autodock 4.0 software, based on Lamarckian Genetic Algorithm; which combines energy evaluation through grids of affinity potential to find the suitable binding position for a ligand on a given protein  {\ref [36]} . Polar hydrogen atoms were added to the protein targets and Kollman united atomic charges were computed. All hydrogen atoms were added to the ligands before the Gastiger partial charges were assigned. The co-crystal ligand was removed and the bond orders were checked. The target's grid map was calculated and set to 60×60×60 points with a grid spacing of 0.375 ?. The grid box was then allocated properly in the target to include the active residue in the center. The default docking algorithms were set in accordance with standard docking protocol  {\ref [37]} . Finally, ten independent docking runs were carried out for each ligand and results were retrieved as binding energies. Poses that showed the lowest binding energies were visualized using the UCSF chimera  {\ref [38]} .\par
III. RESULTS 
\section[{Lujo Virus Glycoprotein GPC Physical and Chemical Parameters}]{Lujo Virus Glycoprotein GPC Physical and Chemical Parameters}\par
The physicochemical properties of the Lujo virus glycoprotein GPC protein was assessed using BioEdit software version 7.0.9.0. The protein length was found to be 454 amino acids. The amino acids that form Lujo virus glycoprotein GPC protein is shown in Figure (2) along with their numbers and molar percentages in (Mol\%).   
\section[{Prediction of T Helper Cell Epitopes and Interaction With MHC Class I Alleles}]{Prediction of T Helper Cell Epitopes and Interaction With MHC Class I Alleles}\par
Lujo virus glycoprotein GPC sequence was analyzed using IEDB MHC class I binding prediction tool based on ANN-align with half-maximal inhibitory concentration (IC 50 ) ?500; the least most promising epitopes that had a binding affinity with the Class I alleles along with their positions in the Lujo virus glycoprotein GPC are shown in Table  {\ref 2}.  
\section[{Prediction of T Helper Cell Epitopes and Interaction With MHC Class II Alleles}]{Prediction of T Helper Cell Epitopes and Interaction With MHC Class II Alleles}\par
Lujo virus glycoprotein GPC sequence was analyzed using IEDB MHC class II binding prediction tool based on NN-align with half-maximal inhibitory concentration (IC 50 ) ?1000. The list of the most promising epitopes, that had a strong binding affinity to MHC class II alleles and depending on the number of their binding alleles are shown in Table  {\ref 3}.        
\section[{Table 3: Most potential T-cell Epitopes with Interacting MHC-Class II Alleles}]{Table 3: Most potential T-cell Epitopes with Interacting MHC-Class II Alleles} 
\section[{IV. DISCUSSION}]{IV. DISCUSSION}\par
In this computational immunoinformatic study we suggest a new promising highly selective peptides vaccine against Lujo virus for the first time according to our findings. We expect to obtain a peptide-based vaccine which implies a high antigenicity and a minimum allergic outcome that is more accurate than the currently used vaccines. The analytical process started after having adequate information on the protein structure of Lujo virus according to the literature review. Simultaneously, though the 3D structure was previously available on the database with all its prospects, we produced our own structure using Raptor X web portal to utilize its complete physiochemical properties information file to confirm our results, and it's a technique we have pursued. The reference sequence of Lujo virus glycoprotein GPC was obtained from the NCBI database. To determine the binding affinity of the conserves epitopes to B-cell and to examine the immunogenicity several tests on the IEDB database were used; the Bepipred linear epitope prediction test, Emini surface accessibility test, and Kolaskar and Tongaonkar antigenicity test were examined. For the Bepipred test of B-cell, the total number of epitopes was 39. For Emini surface accessibility prediction, 29 conserved epitopes were passing the default threshold of 1.0.\par
In Kolaskar and Tongaonkar antigenicity, 7 epitopes provided a score above the default threshold 1.045. However, there are only two epitopes that passed our three tests, which were (LPCPKPHRLR, LPCPKPHR). The reference glycoprotein GPC strain was analyzed using IEDB class MHC-class I binding prediction tool to predict T cell epitope. 165  According to these interesting findings, a very promising vaccine against Lujo virus can potentially be formulated. The most promising three peptides; FWYLNHTKL, LPCPKPHRLR and YMFSVTLCI were docked on to protein target of GPC domain of Lujo virus in complex with the first CUB domain of NRP2 as shown on figure (4  -6). All peptides were docked on the interface of Lujo virus GPC/NRP2 and scored binding energies of -5.84, -3.88 and -8.20 Kcal/mol for peptides 1, 2 and 3, respectively. As the docking results from the analysis of peptide-1 showed binding hydrogen bonding with two amino acid residues: SER-51 and GLN-131 of NRP2. While, Peptide-2 showed a bonding affinity to hydrogen with residues HIS-131 and PHE-137 of Lujo virus GPC and ARG-432 of NRP2, whereas peptide-3 formed hydrogen bonds with PHE-137 of Lujo virus GPC.\par
Only Peptide-2 and 3 interact by forming hydrogen bonding with residues on Lujo virus GPC (HIS-131 and PHE-137). These residues are located at a hydrophobic pocket and adjacent to both residues Val139 and Thr140 of the ?2?4 loop which participates in Van der Waals interactions with NRP2 residues. In addition, histidine residues in the Lujo virus GPC/NRP2 complex are obvious candidates for controlling pH-dependent protein-protein interactions.\par
As for peptide-1, it has formed hydrogen bonds with GLN-131 of NRP2, which is adjacent to the key residue Arg130 that is important for NRP2-fc to recognize Lujo virus GPC-bearing cells and cell entry of Lujo virus \hyperref[b1]{[2]} . The overall docking results analysis has revealed that the peptides are docked at Lujo virus GPC/NRP2 binding surfaces, in which these peptides would serve as potential inhibitors for blocking binding to NRP2 and thus may neutralize the virus. To the best of our knowledge, this study is considered to be the first to propose an epitope-based peptide vaccine against glycoprotein GPC of Lujo virus, which is expected to be highly antigenic with a minimum allergic impact. Furthermore, this study proposes a promising peptide FWYLNHTKL with a very strong binding affinity to MHC1 and MHC11 alleles. This peptide shows exceptional population coverage results for both MHC1 and MHC11 alleles.\par
In-vivo and in-vitro assessments for the most promising peptides namely, FWYLNHTKL, LPCPKPHRLR and YMFSVTLCI are recommended to be explored and studied on their ability to be developed into vaccines against Lujo virus glycoprotein GPC.\begin{figure}[htbp]
\noindent\textbf{1}\includegraphics[]{image-2.png}
\caption{\label{fig_1}Figure 1 :}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{}\includegraphics[]{image-3.png}
\caption{\label{fig_2}}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{2}\includegraphics[]{image-4.png}
\caption{\label{fig_3}Figure 2 :}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{2}\includegraphics[]{image-5.png}
\caption{\label{fig_4}Table 2 :}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{135}\includegraphics[]{image-6.png}
\caption{\label{fig_5}13 3. 5}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{327}\includegraphics[]{image-7.png}
\caption{\label{fig_6}Figure 3 : 2 3. 7}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{4}\includegraphics[]{image-8.png}
\caption{\label{fig_7}Figure 4 :}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{5}\includegraphics[]{image-9.png}
\caption{\label{fig_8}Figure 5 :}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{6}\includegraphics[]{image-10.png}
\caption{\label{fig_9}Figure 6 :}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{}\includegraphics[]{image-11.png}
\caption{\label{fig_10}}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{1} \par 
\begin{longtable}{P{0.04343065693430657\textwidth}P{0.09306569343065693\textwidth}P{0.03722627737226277\textwidth}P{0.1551094890510949\textwidth}P{0.05583941605839416\textwidth}P{0.11788321167883212\textwidth}P{0.08686131386861314\textwidth}P{0.17372262773722627\textwidth}P{0.08686131386861314\textwidth}}
\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep Emini\tabcellsep \tabcellsep Kolasker \&\\
No.\tabcellsep \multicolumn{2}{l}{Start End}\tabcellsep Peptide\tabcellsep Length\tabcellsep \tabcellsep scor\tabcellsep \tabcellsep scor\\
\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep Surfce\tabcellsep \tabcellsep Tongankar\\
\tabcellsep \tabcellsep \tabcellsep LPCPKP\tabcellsep \tabcellsep \tabcellsep \tabcellsep \\
33\tabcellsep 423\tabcellsep 432\tabcellsep \tabcellsep 10\tabcellsep pass\tabcellsep 1.371\tabcellsep pass\tabcellsep 1.088\\
\tabcellsep \tabcellsep \tabcellsep HRLR\tabcellsep \tabcellsep \tabcellsep \tabcellsep \\
\tabcellsep \tabcellsep \tabcellsep LPCPKP\tabcellsep \tabcellsep \tabcellsep \tabcellsep \\
35\tabcellsep 423\tabcellsep 430\tabcellsep \tabcellsep 8\tabcellsep pass\tabcellsep 1.378\tabcellsep pass\tabcellsep 1.095\\
\tabcellsep \tabcellsep \tabcellsep HR\tabcellsep \tabcellsep \tabcellsep \tabcellsep \end{longtable} \par
 
\caption{\label{tab_0}Table 1 :}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{4} \par 
\begin{longtable}{P{0.0029411764705882353\textwidth}P{0.16176470588235295\textwidth}P{0.28823529411764703\textwidth}P{0.16470588235294117\textwidth}P{0.12352941176470589\textwidth}P{0.1088235294117647\textwidth}}
\tabcellsep \tabcellsep \tabcellsep Parts of the World\tabcellsep \\
\tabcellsep MHC classes\tabcellsep Population\tabcellsep World\tabcellsep South Africa\tabcellsep Sudan\\
\tabcellsep \tabcellsep Coverage a\tabcellsep 99.83\%\tabcellsep 99.4\%\tabcellsep 99.41\%\\
\tabcellsep Class I\tabcellsep Average\textunderscore hit b\tabcellsep 32.5\tabcellsep 25.45\tabcellsep 28.25\\
\tabcellsep \tabcellsep PC90 c\tabcellsep 13.28\tabcellsep 8.99\tabcellsep 8.76\\
\tabcellsep \tabcellsep Coverage a\tabcellsep 68.23\%\tabcellsep 32.1\%\tabcellsep 56.38\%\\
\tabcellsep Class II\tabcellsep Average\textunderscore hit b\tabcellsep 55.22\tabcellsep 10.89\tabcellsep 34.14\\
\tabcellsep \tabcellsep PC90 c\tabcellsep -6.57\tabcellsep 4.71\tabcellsep 5.57\\
a\tabcellsep \multicolumn{2}{l}{projected population coverage}\tabcellsep \tabcellsep \end{longtable} \par
 
\begin{quote}
b average number of epitope hits / HLA combinations recognized by the population c minimum number of epitope hits / HLA combinations recognized by 90\% of the population.\end{quote}

\caption{\label{tab_1}Table 4 :}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{5} \par 
\begin{longtable}{P{0.08049242424242424\textwidth}P{0.14488636363636362\textwidth}P{0.07727272727272727\textwidth}P{0.17386363636363636\textwidth}P{0.07727272727272727\textwidth}P{0.07727272727272727\textwidth}P{0.14488636363636362\textwidth}P{0.0740530303030303\textwidth}}
\tabcellsep \tabcellsep \tabcellsep \multicolumn{3}{l}{Population coverage \%/ Area}\tabcellsep \\
\tabcellsep World\tabcellsep \tabcellsep \tabcellsep South Africa\tabcellsep \tabcellsep Sudan\\
Peptide\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep \\
\tabcellsep \tabcellsep MHC I\tabcellsep \tabcellsep \tabcellsep MHC I\tabcellsep \tabcellsep MHC I\\
\tabcellsep MHC I MHC II\tabcellsep \tabcellsep \multicolumn{2}{l}{MHC I MHC II}\tabcellsep \tabcellsep MHC I MHC II\\
\tabcellsep \tabcellsep \& II\tabcellsep \tabcellsep \tabcellsep \& II\tabcellsep \tabcellsep \& II\\
\tabcellsep 56.92\%\tabcellsep 88.77\%\tabcellsep \tabcellsep 5.91\%\tabcellsep 65.72\%\tabcellsep 21.85\%\tabcellsep 80.6\%\\
Ymfsvtlci\tabcellsep 73.92\%\tabcellsep \tabcellsep 63.56\%\tabcellsep \tabcellsep \tabcellsep 75.17\%\\
\tabcellsep 42.99\%\tabcellsep 74.82\%\tabcellsep 41.97\%\tabcellsep 1.79\%\tabcellsep 43.01\%\tabcellsep 35.12\%\tabcellsep 51.56\%\\
Fwylnhtkl\tabcellsep 55.84\%\tabcellsep \tabcellsep \tabcellsep \tabcellsep \tabcellsep 25.35\%\end{longtable} \par
 
\begin{quote}
Epitope -based Peptide Vaccine Against Glycoprotein GPC Precursor of Lujo Virus using Immunoinformatics Approaches\end{quote}

\caption{\label{tab_2}Table 5 :}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{5} \par 
\begin{longtable}{P{0.7909128978224456\textwidth}P{0.03773031825795645\textwidth}P{0.02135678391959799\textwidth}}
\tabcellsep \multicolumn{2}{l}{peptides were predicted}\\
\multicolumn{3}{l}{to interact with different class MHC-class I}\\
\multicolumn{3}{l}{alleles. For class MHC-class II binding}\\
\multicolumn{3}{l}{prediction, there were 315 epitopes found to}\\
\multicolumn{3}{l}{interact with class MHC-class II alleles. The}\\
peptides\tabcellsep YMFSVTLCI,\tabcellsep LMFSVSFYM,\\
RLQEAVSTL,\tabcellsep FQLVIFLLL,\tabcellsep MSLLSSIPM,\\
\multicolumn{3}{l}{VIFDLFREF, ITFSLLTNK, ILMFSVSFY and}\\
\multicolumn{3}{l}{FWYLNHTKL had the affinity to bind with the}\\
\multicolumn{3}{l}{highest number of class MHC-class I alleles. The}\\
peptides\tabcellsep FWYLNHTKL,\tabcellsep YMFSVTLCI,\\
\multicolumn{3}{l}{FNMSLLSSI, INAIISDTL, LMKLFQWSL and}\\
\multicolumn{3}{l}{VFQAIPEIL had the affinity to bind with the}\\
\multicolumn{3}{l}{highest number of class MHC-class II alleles.}\\
\multicolumn{3}{l}{The most promising three peptides for both class}\\
\multicolumn{3}{l}{MHC-class I and MHC-class II were}\\
\multicolumn{3}{l}{FWYLNHTKL, LPCPKPHRLR and YMFSVTLCI}\\
\multicolumn{3}{l}{as shown on figure (3). On the other hand, the}\\
\multicolumn{3}{l}{world Population coverage of all epitopes that}\\
\multicolumn{3}{l}{bind to MHC-class I were found to be 99.83\%,}\\
\multicolumn{3}{l}{while the world population coverage of all}\\
\multicolumn{3}{l}{epitopes that bind to MHC-class II were 68.23\%}\\
\multicolumn{3}{l}{as presented in table 4. For the binding affinity to}\\
\multicolumn{3}{l}{MHC-class I and MHC-class II the peptide}\\
\multicolumn{3}{l}{FWYLNHTKL was found to bind 14 different}\\
\multicolumn{3}{l}{alleles of MHC-class II \& five alleles of MHC-}\\
\multicolumn{3}{l}{class I, that gave a world population coverage of}\\
\multicolumn{3}{l}{74.82\% , 43.01\% for South Africa and 51.56\% for}\\
\multicolumn{3}{l}{Sudan of both MHC class I and II as shown on}\end{longtable} \par
 
\caption{\label{tab_3}table 5 .}\end{figure}
 			\label{foot_0}\footnote{\label{foot_0} | | Volume 23 Issue 2 ?"? Compilation 1.0 © 2023 Great ] Britain Journals Press} 			\label{foot_1}\footnote{\label{foot_1} Epitope -based Peptide Vaccine Against Glycoprotein GPC Precursor of Lujo Virus using Immunoinformatics Approaches} 			\label{foot_2}\footnote{\label{foot_2} | | Volume 23 Issue 2 ?"? Compilation 1.0 © 2023 Great ] Britain Journals Press} 		 		\backmatter  			 
\subsection[{Competing Interests}]{Competing Interests}\par
The authors declare that they have no competing interests. 			 			  				\begin{bibitemlist}{1}
\bibitem[ London Journal of Research in Computer Science and Technology]{b34}\label{b34} 	 		\textit{},  	 	 		\textit{London Journal of Research in Computer Science and Technology}  		 	 
\bibitem[Oyarzun et al. ()]{b16}\label{b16} 	 		‘A bioinformatics tool for epitope-based vaccine design that accounts for human ethnic diversity: Application to emerging infectious diseases’.  		 			P Oyarzun 		,  		 			J J Ellis 		,  		 			F F Gonzalez-Galarza 		,  		 			A R Jones 		,  		 			D Middleton 		,  		 			M Boden 		,  		 			B Kobe 		.  	 	 		\textit{Vaccine}  		2015. 33  (10)  p. .  	 
\bibitem[Kolaskar and Tongaonkar ()]{b23}\label{b23} 	 		‘A semi-empirical method for prediction of anti-genic determinants on protein antigens’.  		 			A S Kolaskar 		,  		 			P C Tongaonkar 		.  	 	 		\textit{FEBS Lett}  		1990. 276  (1-2)  p. .  	 
\bibitem[Ko?alo?lu-Yalç?n et al. (1492508)]{b27}\label{b27} 	 		‘Alessandro Sette \& Bjoern Peters (2018) Predicting T cell recognition of MHC class I restricted neoepitopes’.  		 			Zeynep Ko?alo?lu-Yalç?n 		,  		 			Manasa Lanka 		,  		 			Angela Frentzen 		,  		 			Ashmitaa Logandha 		,  		 			Ramamoorthy Premlal 		,  		 			John Sidney 		,  		 			Kerrie Vaughan 		,  		 			Jason Greenbaum 		,  		 			Paul Robbins 		,  		 			Jared Gartner 		.  		 \xref{http://dx.doi.org/10.1080/2162402X.2018.1492508}{10.1080/2162402X.2018.1492508}.  	 	 		\textit{OncoImmunology}  		1492508. 7  (11) .  	 
\bibitem[Tani ()]{b8}\label{b8} 	 		‘Analysis of Lujo virus cell entry using pseudotype vesicular stomatitis virus’.  		 			H Tani 		.  	 	 		\textit{J Virol}  		2014. 88  (13)  p. .  	 
\bibitem[Hall ()]{b19}\label{b19} 	 		‘BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT’.  		 			T A Hall 		.  	 	 		\textit{Nucl Acids Symp Ser}  		1999. 41 p. .  	 
\bibitem[Choo et al. ()]{b30}\label{b30} 	 		‘Bioorthogonal cleavage and exchange of major histocompatibility complex ligands by employing azobenzene-containing peptides’.  		 			J A Choo 		,  		 			S Y Thong 		,  		 			J Yap 		,  		 			W J Van Esch 		,  		 			M Raida 		,  		 			R Meijers 		,  		 			J Lescar 		,  		 			S H Verhelst 		,  		 			G M Grotenbreg 		.  	 	 		\textit{Angew. Chem}  		2014. 53 p. .  	 
\bibitem[Paul et al. ()]{b26}\label{b26} 	 		‘Bjoern Peters and Alessandro Sette’.  		 			Sinu Paul 		,  		 			Daniela Weiskopf 		,  		 			Michael A Angelo 		,  		 			John Sidney 		.  		 \xref{http://dx.doi.org/10.4049/jimmunol.1302101}{10.4049/jimmunol.1302101}.  		 \url{https://doi.org/10.4049/jimmunol.1302101}  	 	 		\textit{J Immunol December}  		2013. 15  (12)  p. .  	 
\bibitem[Kunz and De La ()]{b2}\label{b2} 	 		‘Breaking the Barrier: Host Cell Invasion by Lujo Virus’.  		 			S Kunz 		,  		 			J C De La 		,  		 			Torre 		.  	 	 		\textit{Cell Host Microbe}  		2017. 22  (5)  p. .  	 
\bibitem[Sewlall ()]{b3}\label{b3} 	 		‘Clinical features and patient management of Lujo hemorrhagic fever’.  		 			N H Sewlall 		.  	 	 		\textit{PLoS Negl Trop Dis}  		2014. 8  (11)  p. 3233.  	 
\bibitem[Bui et al. ()]{b20}\label{b20} 	 		‘Development of an epitope conservancy analysis tool to facilitate the design of epitope-based diagnostic sand vaccines’.  		 			H H Bui 		,  		 			J Sidney 		,  		 			W Li 		,  		 			N Fusseder 		,  		 			A Sette 		.  	 	 		\textit{BMC Bioinform}  		2007. 8  (1)  p. 361.  	 
\bibitem[Beyer et al. ()]{b5}\label{b5} 	 		‘Endoproteolytic processing of the lymphocytic choriomeningitis virus glycoprotein by the subtilase SKI-1/S1P’.  		 			W R Beyer 		,  		 			D Popplau 		,  		 			W Garten 		,  		 			Von Laer 		,  		 			D Lenz 		,  		 			O 		.  	 	 		\textit{J Virol}  		2003. 77  (5)  p. .  	 	 (PubMed:125843 10) 
\bibitem[Mohammed ()]{b11}\label{b11} 	 		‘Epitope-Based Peptide Vaccine Against Fructose-Bisphosphate Aldolase of Madurella mycetomatis Using Immunoinformatics Approaches’.  		 			A A Mohammed 		.  	 	 		\textit{Bioinform Biol Insights}  		2018. 12 p. 1177932218809703.  	 
\bibitem[Mohammed et al. ()]{b13}\label{b13} 	 		‘Epitope-Based Peptide Vaccine against Glycoprotein G of Nipah Henipavirus Using Immunoinformatics Approaches’.  		 			A A Mohammed 		,  		 			S W Shantier 		,  		 			M I Mustafa 		,  		 			H K Osman 		,  		 			H E Elmansi 		,  		 			I A A Osman 		,  		 			M A Hassan 		.  		 \xref{http://dx.doi.org/10.1155/2020/2567957}{10.1155/2020/2567957}.  		 \url{https://doi.org/10.1155/2020/2567957}  	 	 		\textit{Journal of Immunology Research}  		2020. 2020.  	 
\bibitem[Mohammed et al. ()]{b10}\label{b10} 	 		‘Epitope-Based PeptideVaccine Design Against Mokola Rabies Virus Glycoprotein G Utilizing In Silico Approaches’.  		 			A A Mohammed 		,  		 			O Hashim 		,  		 			Kaa Elrahman 		,  		 			A Hamdi 		,  		 			M A Hassan 		.  		 \xref{http://dx.doi.org/10.4172/1745-7580.1000144}{10.4172/1745-7580.1000144}.  	 	 		\textit{Immunome Res}  		2017. 13 p. 144.  	 
\bibitem[Badawi et al. ()]{b14}\label{b14} 	 		‘Highly Conserved Epitopes of ZIKA Envelope Glycoprotein May Act as a Novel Peptide Vaccine with High Coverage: Immunoinformatics Approach’.  		 			M M Badawi 		,  		 			M M Osman 		,  		 			Aaf Alla 		,  		 			A M Ahmedani 		,  		 			Abdalla Mh 		,  		 			M M Gasemelseed 		.  	 	 		\textit{American Journal of Biomedical Research}  		2016. 4  (3)  p. .  	 
\bibitem[Shao ()]{b4}\label{b4} 	 		‘Human hemorrhagic Fever causing arenaviruses: molecular mechanisms contributing to virus virulence and disease pathogenesis’.  		 			J Shao 		.  	 	 		\textit{Pathogens}  		2015. 4  (2)  p. .  	 
\bibitem[Kim et al. ()]{b25}\label{b25} 	 		‘Immune epitope database analysis resource’.  		 			Y Kim 		,  		 			J Ponomarenko 		,  		 			Z Zhu 		,  		 			D Tamang 		,  		 			P Wang 		.  	 	 		\textit{Nucleic Acids Res}  		2012. 40 p. .  	 
\bibitem[Zhang et al. ()]{b29}\label{b29} 	 		‘Immune epitope database analysis resource (IEDB-AR)’.  		 			Q Zhang 		,  		 			P Wang 		,  		 			Y Kim 		,  		 			P Haste-Andersen 		,  		 			J Beaver 		.  	 	 		\textit{Nucleic Acids Res}  		2008. 36 p. .  	 
\bibitem[Hashim et al. ()]{b9}\label{b9} 	 		‘Immuno informatic Approach for Epitope-Based Peptide Vaccine against Lagos Rabies Virus Glycoprotein G’.  		 			Omar Hashim 		,  		 			Ahmed 		,  		 			Arwa Abdelhalim 		,  		 			Sahar Obi 		,  		 			Khoubieb Ali Abdelrahman 		,  		 			Ahmed Hamdi 		,  		 			Mohammed A Hassan 		.  		 \xref{http://dx.doi.org/10.4172/1745-7580.1000137}{10.4172/1745-7580.1000137}.  	 	 		\textit{Immunome Research}  		2017. 08.  	 
\bibitem[Larsen et al. ()]{b21}\label{b21} 	 		‘Improved method for predicting linear B-cell epitopes’.  		 			J E Larsen 		,  		 			O Lund 		,  		 			M Nielsen 		.  	 	 		\textit{Immunome Res}  		2006. 2  (2) .  	 
\bibitem[Emini et al. ()]{b22}\label{b22} 	 		‘Induction of hepatitis A virusneutralizing antibody by a virus-specific synthetic peptide’.  		 			E A Emini 		,  		 			J V Hughes 		,  		 			D S Perlow 		,  		 			J Boger 		.  	 	 		\textit{J. Virol}  		1985. 55  (3)  p. .  	 
\bibitem[Li et al. ()]{b15}\label{b15} 	 		 			W Li 		,  		 			M Joshi 		,  		 			S Singhania 		,  		 			K Ramsey 		,  		 			A Murthy 		.  	 	 		\textit{Peptide Vaccine: Progress and Challenges},  		2014. 2 p. .  	 
\bibitem[Laimer and Lackner ()]{b28}\label{b28} 	 		‘MHCII3D-Robust Structure Based Prediction of MHC II Binding Peptides’.  		 			J Laimer 		,  		 			P Lackner 		.  		 \xref{http://dx.doi.org/10.3390/ijms22010012}{10.3390/ijms22010012}.  		 \url{https://doi.org/10.3390/ijms22010012}  	 	 		\textit{International Journal of Molecular Sciences}  		2021. 22  (1)  p. 12.  	 
\bibitem[NCBI protein sequence database ()]{b17}\label{b17} 	 		\textit{NCBI protein sequence database},  		 \url{https://www.ncbi.nlm.nih.gov/protein}  		2018.  	 
\bibitem[Skwarczynski and Toth ()]{b12}\label{b12} 	 		‘Peptide-based synthetic vaccines’.  		 			M Skwarczynski 		,  		 			I Toth 		.  	 	 		\textit{Chemical science}  		2016. 7  (2)  p. .  	 
\bibitem[Pinschewer et al. ()]{b6}\label{b6} 	 		‘Recombinant lymphocytic choriomeningitis virus expressing vesicular stomatitis virus glycoprotein’.  		 			D D Pinschewer 		,  		 			M Perez 		,  		 			A B Sanchez 		,  		 			J C De La Torre 		.  	 	 		\textit{Proc Natl Acad Sci U S A}  		2003. 100  (13)  p. .  	 	 (PubMed: 12808132) 
\bibitem[Nielsen et al. ()]{b24}\label{b24} 	 		‘Reliable prediction of T-cell epitopes using neural networks with novel sequence representations’.  		 			M Nielsen 		,  		 			C Lundegaard 		,  		 			P Worning 		,  		 			S L Lauemøller 		,  		 			K Lamberth 		.  	 	 		\textit{Protein Sci}  		2003. 12 p. .  	 
\bibitem[Bergeron ()]{b0}\label{b0} 	 		‘Reverse genetics recovery of Lujo virus and role of virus RNA secondary structures in efficient virus growth’.  		 			E Bergeron 		.  	 	 		\textit{J Virol}  		2012. 86  (19)  p. .  	 
\bibitem[Rojek et al. ()]{b7}\label{b7} 	 		‘Site 1 protease is required for proteolytic processing of the glycoproteins of the South American hemorrhagic fever viruses Junin, Machupo, and Guanarito’.  		 			J M Rojek 		,  		 			A M Lee 		,  		 			N Nguyen 		,  		 			C F Spiropoulou 		,  		 			S Kunz 		.  	 	 		\textit{J Virol}  		2008. 82  (12)  p. .  	 	 (PubMed: 18400865) 
\bibitem[Cohen-Dvashi ()]{b1}\label{b1} 	 		‘Structural basis for receptor recognition by Lujo virus’.  		 			H Cohen-Dvashi 		.  	 	 		\textit{Nat Microbiol}  		2018. 3  (10)  p. .  	 
\bibitem[Goddard and Huang ()]{b32}\label{b32} 	 		‘TE Software extensions to UCSF chimera for interactive visualization of large molecular assemblies’.  		 			Td1 Goddard 		,  		 			C C Huang 		,  		 			Ferrin 		.  	 	 		\textit{J Structure}  		2005. 13  (3)  p. .  	 
\bibitem[Källberg et al. ()]{b31}\label{b31} 	 		‘Temple-based protein structure modelling using the RaptorX website server’.  		 			M Källberg 		,  		 			H Wang 		,  		 			S Wang 		,  		 			J Peng 		,  		 			Z Wang 		,  		 			H Lu 		,  		 			H Xu 		.  	 	 		\textit{Nature Protocols}  		2012. 7 p. .  	 
\bibitem[Vita et al. (2014)]{b18}\label{b18} 	 		‘The immune epitope database (IEDB) 3.0’.  		 			R Vita 		,  		 			J A Overton 		,  		 			J A Greenbaum 		,  		 			J Ponomarenko 		,  		 			J D Clark 		,  		 			J R Cantrell 		,  		 			D K Wheeler 		,  		 			J L Gabbard 		,  		 			D Hix 		,  		 			A Sette 		,  		 			B Peters 		.  		 25300482.  	 	 		\textit{Nucleic Acids Res}  		2014 Oct 9. 938.  	 	 (Epub ahead of print) 
\bibitem[Zheng et al.]{b33}\label{b33} 	 		 			J Zheng 		,  		 			X Lin 		,  		 			X Wang 		,  		 			L Zheng 		,  		 			S Lan 		,  		 			Jin S Ou 		,  		 			Z Wu 		,  		 			J 		.  		 \xref{http://dx.doi.org/10.1155/2020/2567957}{10.1155/2020/2567957}.  		\textit{Silico Analysis of Epitope-Based Vaccine Candidates against Hepatitis B Virus Polymerase Protein. Viruses},  		 	 
\end{bibitemlist}
 			 		 	 
\end{document}
